Work

Abstract PS3-10-21: Should genomic risk guide the use of adjuvant CDK4-6i in N0-N1 HR+ and HER2− early breast cancer?

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps3-10-21

Authors: M. Iglesias Campos, J. Pascual López, A. Sánchez-Muñoz, N. Ribelles Entrena, M. J. Bermejo Pérez, A. Márquez Aragonés, B. Pajares Hachero, M. E. Domínguez Recio, A. Godoy Ortiz, B. Jiménez Rodríguez, F. Carabantes Ocón, T. Díaz Redondo, E. Villar Chamorro, P. Cantizani Maíllo, E. Alba Conejo

Institutions: Hospital Clínico Universitario Virgen de la Victoria, Hospital Regional Universitario de Málaga

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129200694

Cites:

Cited by:

Related to: